Merck & Co., Inc. (MRK) Presents at HIV Investor Event Transcript

Merck outlined its comprehensive HIV pipeline strategy at a recent investor event, emphasizing four late-stage programs centered on its novel NRTTI class, including islatravir and MK-8527. Key candidates include the daily oral doravirine/islatravir, for which an NDA has been filed with an April 2026 PDUFA date, and two weekly oral treatments: islatravir/lenacapavir (in partnership with Gilead) and the wholly-owned islatravir/ulonivirine. Additionally, the company is advancing MK-8527, a monthly oral PrEP option entering Phase III, aiming to address significant unmet needs by offering simplified, long-acting regimens with high barriers to resistance and favorable drug-drug interaction profiles, projecting over $5 billion in revenue from this portfolio by the mid-2030s.

Analysis

Merck & Co. has detailed a comprehensive late-stage HIV pipeline that it projects will generate over $5 billion in non-risk-adjusted revenue by the mid-2030s, signaling a major strategic focus for the company. The pipeline is anchored by its novel nucleoside reverse transcriptase translocation inhibitor (NRTTI) class of medicines, which are positioned to offer high potency, long-acting profiles, and a high barrier to resistance. The company highlighted four key programs: a once-daily oral treatment, doravirine/islatravir, for which a New Drug Application (NDA) has been accepted by the FDA with a PDUFA date of April 28, 2026; a once-weekly oral treatment, islatravir/lenacapavir, developed in partnership with Gilead and currently in Phase III with data expected in mid-2026; a wholly-owned once-weekly oral treatment, islatravir/ulonivirine (Phase II); and a once-monthly oral PrEP candidate, MK-8527, which is entering Phase III trials. These programs aim to address significant unmet needs in the HIV market, including treatment simplification with two-drug, integrase-sparing regimens, reduced pill burden for improved adherence, and discreet prevention options to combat stigma. Management's confidence is supported by market research indicating that approximately one-third of individuals would prefer long-acting oral options for both treatment and prevention, positioning Merck to compete for substantial share in a market increasingly moving towards convenience and simplified regimens.

Key Decisions for Investors

• Investors should monitor a series of key catalysts for Merck's HIV franchise, including the PDUFA decision for doravirine/islatravir on April 28, 2026, and the readout of Phase III data for the weekly islatravir/lenacapavir regimen in mid-2026, as these events will be crucial in validating the projected multi-billion dollar revenue opportunity.
• The success of this pipeline hinges on its ability to differentiate and capture share from established therapies, particularly by demonstrating the clinical and commercial value of its two-drug, integrase inhibitor-free, and long-acting oral regimens against incumbents like Gilead's Biktarvy and injectable PrEP options.
• The monthly oral PrEP candidate, MK-8527, represents a significant potential growth driver, and its Phase III progress and eventual market adoption should be watched closely as a test of Merck's ability to expand the PrEP market beyond current daily orals and injectables.
• Given that management believes its HIV pipeline is underappreciated, investors may consider re-evaluating long-term models for Merck to account for the potential upside from the greater than $5 billion revenue guidance, which may not be fully reflected in current consensus estimates.